Create Free Account

By creating account you will get access to hot stocks & personalised emails

Medibank Private Ltd

Financial Services AU MPL

3.78AUD
0.02(0.53%)

Last update at 2024-12-19T05:11:00Z

Day Range

3.733.78
LowHigh

52 Week Range

3.333.97
LowHigh

Fundamentals

  • Previous Close 3.76
  • Market Cap10299.96M
  • Volume7010888
  • P/E Ratio20.78
  • Dividend Yield4.39%
  • EBITDA738.10M
  • Revenue TTM8029.70M
  • Revenue Per Share TTM2.92
  • Gross Profit TTM 1635.20M
  • Diluted EPS TTM0.18

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 727.10M 560.00M 632.30M 450.20M 616.30M
Minority interest - - - - -
Net income 511.10M 393.90M 441.20M 315.00M 458.70M
Selling general administrative 671.00M 666.10M 664.50M 648.80M 619.60M
Selling and marketing expenses 115.50M 85.90M 81.40M 94.10M 100.20M
Gross profit 7499.30M 7092.40M 7011.00M 6778.60M 6752.30M
Reconciled depreciation 118.40M 115.00M 82.70M 88.80M 64.10M
Ebit 608.70M 445.00M 549.60M 361.40M 637.30M
Ebitda 727.10M 560.00M 632.30M 450.20M 701.40M
Depreciation and amortization 118.40M 115.00M 82.70M 88.80M 64.10M
Non operating income net other - - - - -
Operating income 608.70M 445.00M 549.60M 361.40M 637.30M
Other operating expenses 6772.20M 6532.40M 6378.70M 6328.40M 6136.00M
Interest expense 1.80M 2.40M 2.40M 0.00000M 0.00000M
Tax provision 216.00M 166.10M 191.10M 134.60M 178.60M
Interest income 3.20M 17.90M 17.70M 3.40M 47.30M
Net interest income -1.80000M -2.40000M -2.80000M -3.40000M -
Extraordinary items - - 0.00000M -0.60000M 21.00M
Non recurring - - - - -
Other items - - - - -
Income tax expense 216.00M 166.10M 191.10M 134.60M 178.60M
Total revenue 7499.30M 7092.40M 7011.00M 6778.60M 6752.30M
Total operating expenses 6766.00M 6542.30M 6397.10M 6325.80M -6115.00000M
Cost of revenue - - - - 5323.60M
Total other income expense net 174.30M 248.30M 221.10M 222.30M -21.00000M
Discontinued operations - - - -0.60000M 21.00M
Net income from continuing ops 511.10M 393.90M 441.20M 315.60M 437.70M
Net income applicable to common shares 511.10M 393.90M 441.20M 315.00M 458.70M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 4685.40M 4388.80M 4552.80M 3923.80M 3763.80M
Intangible assets - 123.60M 127.80M 140.80M 181.50M
Earning assets - - - - -
Other current assets 3778.70M 42.70M 2737.10M 1978.70M 1590.30M
Total liab 2380.30M 215.70M 2607.20M 2017.70M 1949.90M
Total stockholder equity 2305.70M 2084.40M 1945.60M 1906.10M 1813.90M
Deferred long term liab - - - - -
Other current liab 85.10M -215.70000M -241.40000M -239.90000M -230.20000M
Common stock 85.00M 85.00M 85.00M 85.00M 85.00M
Capital stock - 85.00M 85.00M 85.00M 85.00M
Retained earnings 2068.40M 1971.50M 1834.90M 1798.80M 1706.50M
Other liab - 177.30M 120.50M 97.10M 117.70M
Good will 323.70M 204.50M 204.50M 204.50M 204.50M
Other assets 0.00000M 3490.50M 3452.50M 2724.00M 2338.40M
Cash 691.00M 420.60M 596.70M 671.70M 871.40M
Cash and equivalents - 420.60M 596.70M 671.70M 871.40M
Total current liabilities 2000.30M 215.70M 241.40M 239.90M 230.20M
Current deferred revenue 48.70M - - - -
Net debt -472.70000M -420.60000M -596.70000M -671.70000M -871.40000M
Short term debt 66.60M 0.00000M 0.00000M 0.00000M 298.40M
Short long term debt - - - - -
Short long term debt total 218.30M - - 65.30M 81.30M
Other stockholder equity - -2056.50000M -1919.90000M -1883.80000M -1775.40000M
Property plant equipment - 70.50M 88.40M 101.70M 112.20M
Total current assets 3778.70M 420.60M 596.70M 671.70M 871.40M
Long term investments - 392.10M 338.30M 343.80M 298.40M
Net tangible assets - 1756.30M 1613.30M 1560.80M 1427.90M
Short term investments 3048.20M 274.50M 234.60M 266.70M 298.40M
Net receivables - 248.10M 225.40M 215.90M 207.10M
Long term debt - - - - -
Inventory - - -3197.10000M -2461.30000M -2095.80000M
Accounts payable 1799.90M 215.70M 241.40M 239.90M 230.20M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 152.30M 27.90M 25.70M 22.30M 22.40M
Additional paid in capital - - - - -
Common stock total equity - - - - 85.00M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -2858.80000M -477.70000M -503.60000M -528.10000M -554.00000M
Deferred long term asset charges - - - - -
Non current assets total 906.70M 477.70M 503.60M 528.10M 554.00M
Capital lease obligations - - - - -
Long term debt total - 24.40M 46.70M 65.30M 81.30M
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Investments -110.80000M 58.50M -602.70000M -284.10000M 110.70M
Change to liabilities - 99.20M 14.50M 31.30M -157.60000M
Total cashflows from investing activities - 58.50M -623.60000M -306.10000M 109.20M
Net borrowings - -39.70000M -38.80000M -37.00000M -33.30000M
Total cash from financing activities -487.30000M -419.10000M -399.90000M -375.80000M -466.70000M
Change to operating activities - -180.50000M 282.80M 71.40M 228.10M
Net income 3.90M 511.10M 393.90M 441.20M 315.00M
Change in cash 270.40M -176.10000M -75.00000M -199.70000M 214.90M
Begin period cash flow 420.60M 596.70M 671.70M 871.40M 656.50M
End period cash flow 691.00M 420.60M 596.70M 671.70M 871.40M
Total cash from operating activities 868.50M 184.50M 948.50M 482.20M 572.40M
Issuance of capital stock - - - - -
Depreciation 89.40M 40.70M 41.20M 45.10M 49.20M
Other cashflows from investing activities - 100.40M 14.20M 13.10M 27.80M
Dividends paid 426.90M 374.50M 358.00M 333.20M 429.60M
Change to inventory - - - - -
Change to account receivables 9.90M -22.00000M -11.10000M -8.80000M 9.90M
Sale purchase of stock -7.50000M -4.90000M -3.10000M -5.60000M -3.80000M
Other cashflows from financing activities -51.60000M -39.70000M -38.80000M -37.00000M -33.30000M
Change to netincome - -126.90000M 30.20M -111.00000M 13.80M
Capital expenditures 57.60M 41.90M 35.10M 35.10M 29.30M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 330.20M -22.00000M -11.10000M -8.80000M 9.90M
Stock based compensation 3.30M 6.70M 5.90M 5.20M 1.64M
Other non cash items 445.00M -367.30000M 513.40M -4.10000M 208.20M
Free cash flow 810.90M 142.60M 913.40M 447.10M 543.10M

Peer Comparison

Sector: Financial Services Industry: Insurance - Specialty

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MPL
Medibank Private Ltd		 0.02 0.53% 3.78 20.78 16.42 1.28 4.51 1.24 -
NHF
NIB Holdings		 0.02 0.37% 5.49 14.68 15.50 0.79 2.59 0.80 -
HLI
Helia Group Limited		 -0.03 0.67% 4.45 5.96 5.47 2.51 1.16 2.65 -

Reports Covered

Stock Research & News

View All

Profile

Medibank Private Limited provides private health insurance and health services in Australia. The company operates in two segments, Health Insurance and Medibank Health. The Health Insurance segment provides private health insurance products, including hospital cover that offers members with health cover for hospital treatments; and ancillary cover, which provides members with health cover for healthcare services, such as dental, optical, and physiotherapy. This segment also offers health insurance products to overseas visitors and overseas students. The Medibank Health segment provides health management and in-home care services, as well as a range of telehealth services to government and corporate customers; and distributes travel, life, and pet insurance products. It underwrites its health insurance products under the Medibank and ahm brands. The company was founded in 1976 and is based in Docklands, Australia.

Medibank Private Ltd

695 Collins Street, Docklands, VIC, Australia, 3008

Key Executives

Name Title Year Born
Mr. David Koczkar B.Com., BCom, MAICD, PGDipFinance CEO, MD & Director 1973
Mr. Mark Rogers B.Sc., BEng (Hons), BSc Group Exec. of CFO & Group Strategy NA
Dr. Andrew Wilson FACHSE, FRANZCP, M.M., MBBS, MM Group Exec. & CEO of Amplar Health NA
Mr. Milosh Milisavljevic Group Exec. of Customer Portfolios NA
Mr. John Goodall B.Sc., BSc (Hons) Group Exec. of Technology & Operations NA
Mr. Peter Kopanidis Sr. Exec. of Corp. Fin. NA
Colette Campbell Sr. Exec. of Investor Relations NA
Ms. Mei Ramsay B.A., BA, L.L.B., L.L.M., LLB, LLM Group Exec. of Legal, Governance & Compliance and Company Sec. NA
Emily Ritchie Sr. Exec. of External Affairs NA
Ms. Kylie Bishop B.A., BA (Hons) Psy, MOrgPsych Group Exec. of People, Culture & Sustainability NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.